Rp-8-CPT-cAMPS, a cAMP analog, is a potent and competitive antagonist of cAMP-induced activation of cAMP-dependent PKA I and II. Rp-8-CPT-cAMPS preferentially selects site A of RI compares to site A of RII and site B of RII compares to site B of RI.

Product information

CAS Number: 129735-01-9

Molecular Weight: 487.88

Formula: C16H15ClN5O5PS2

Chemical Name: (2R, 4aR, 6R, 7R, 7aS)-6-{6-amino-8-[(4-chlorophenyl)sulfanyl]-9H-purin-9-yl}-7-hydroxy-2-sulfanyl-hexahydro-2-furo[3, 2-d][1, 3, 2]dioxaphosphinin-2-one

Smiles: NC1=NC=NC2=C1N=C(SC1C=CC(Cl)=CC=1)N2[C@@H]1O[C@@H]2CO[P@@](=O)(S)O[C@H]2[C@H]1O

InChiKey: IVNQJYQKSYRLTE-FUWBYEKLSA-N

InChi: InChI=1S/C16H15ClN5O5PS2/c17-7-1-3-8(4-2-7)30-16-21-10-13(18)19-6-20-14(10)22(16)15-11(23)12-9(26-15)5-25-28(24,29)27-12/h1-4,6,9,11-12,15,23H,5H2,(H,24,29)(H2,18,19,20)/t9-,11-,12-,15-,28-/m1/s1

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: Soluble in DMSO

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

Rp-8-CPT-cAMPS (100 μM; 15 min) blocks phosphorylation of VASP by 6-Bnz-cAMP and largely reduces VASP phosphorylation by forskolin and fenoterol. Rp-8-CPT-cAMPS (100 μM; 30 min) reduces GTP-loading of Rap1 by both 8-pCPT-2'-O-Me-cAMP and 6-Bnz-cAMP. Rp-8-CPT-cAMPS (100 μM; 30 min) largely diminishes the augmentation of bradykinin-induced IL-8 release by the PKA activator 6-Bnz-cAMP and the Epac activator 8-pCPT-2'-O-Me-cAMP. Rp-8-CPT-cAMPS (10 μM) inhibits the endothelium-dependent and -independent relaxation which induced by Venom in pre-contracted rat mesenteric artery rings.

References:

1. Dostmann WR , et, al. Probing the cyclic nucleotide binding sites of cAMP-dependent protein kinases I and II with analogs of adenosine 3',5'-cyclic phosphorothioates. J Biol Chem. 1990 Jun 25;265(18):10484-91.
2. Roscioni SS, et, al. PKA and Epac cooperate to augment bradykinin-induced interleukin-8 release from human airway smooth muscle cells. Respir Res. 2009 Sep 29;10(1):88.

Products are for research use only. Not for human use.